News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Corstasis Therapeutics Inc. Announces FDA Approval of New Drug Application for Bumetanide Nasal Spray
Monday, January 27, 2025Corstasis Therapeutics Inc a clinicalstage MedTech pharmaceutical company focused on developing practical treatments for fluid overload has announced that the US Food and Drug Administration FDA has accepted the New Drug Application NDA for its innov...
MilliporeSigma Collaborates with Opentrons Labworks, Inc. to Support the Laboratory of the Future
Friday, January 24, 2025MilliporeSigma the Life Science business of Merck KGaA Darmstadt Germany in the US and Canada has signed a multiyear agreement with Opentrons Labworks Inc a leader in laboratory automation and robotics to automate assay kits using a customised Opentr...
Zai Lab Granted Orphan Drug Status by U.S. FDA for ZL-1310 (DLL3 ADC) in Treating Small Cell Lung Cancer (SCLC)
Thursday, January 23, 2025Zai Lab Limitedannounced that the US Food and Drug Administration FDA has granted Orphan Drug Designation ODD to ZL a novel and potentially firstinclass DLL antibodydrug conjugate ADC for treating small cell lung cancer SCLC
Altamira Therapeutics Reveals Partnership on Radiopharmaceutical Targeting Approaches
Thursday, January 23, 2025Altamira Therapeutics Ltda company focused on developing and commercialising RNA delivery technology for targets beyond the liver has announced a collaboration with a radiopharmaceutical company to explore the potential use of its RNA delivery platfo...
Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma
Wednesday, January 22, 2025Following the adoption of a positive opinion by the European Medicines Agencys EMA Committee for Medicinal Products for Human Use CHMP the EU has approved Sarclisa in combination with a standardofcare regimen bortezomib lenalidomide and dexamethasone...
European Commission approves LAZCLUZE® (lazertinib) in combination with RYBREVANT® (amivantamab) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer
Wednesday, January 22, 2025JanssenCilag International NV a Johnson Johnson company today announced that the European Commission EC has approved a Marketing Authorisation MA for LAZCLUZE lazertinib in combination with RYBREVANT amivantamab for the firstline treatment of adult...
Junshi Biosciences Announces Commercialization Partnership with LEO Pharma for Toripalimab in Europe
Tuesday, January 21, 2025Shanghai Junshi Biosciences Co Ltd a leading innovationdriven biopharmaceutical company dedicated to the discovery development and commercialization of novel therapies and its whollyowned subsidiary
Serina Therapeutics Announces Sale of UniverXome Subsidiary
Friday, January 17, 2025Serina Therapeutics Inc a clinicalstage biotechnology company developing its proprietary POZ Platform drug delivery technology today announced the sale of its UniverXome subsidiary The transaction was finalized on December and eliminated million i...
Illuccix® Receives European Approval
Friday, January 17, 2025Telix Pharmaceuticals Limited announces that it has received a positive decision on the Marketing Authorization Application MAA for its prostate cancer PET imaging agent Illuccix kit for the preparation of gallium gozetotide injection which was submi...
Axcynsis Therapeutics Receives FDA Clearance for IND Application of AT03-65, a Differentiated CLDN6-Targeting ADC, Powered by AxcynDOT™ Technology
Thursday, January 16, 2025Axcynsis Therapeutics Pte Ltda privately held biopharmaceutical company specialized in delivering Antibody Drug Conjugates ADCs with breakthrough potential proudly announces the clearance of its Investigational New Drug application
